Antev Ltd.

4 clinical trials · Sponsor

Record	Firm	Date
Study of Teverelix DP on Prostate Volume, Urinary Function and Clinical Outcomes Following Acute Urinary Retention (NCT07733934)	Antev Ltd.	2026-09-01
A Study Investigating the Pharmacokinetics, Pharmacodynamics, Efficacy and Safety of Teverelix DP, a Gonadotropin-releasing Hormone (GnRH) Antagonist, in Patients With Advanced Prostate Cancer (NCT07457164)	Antev Ltd.	2026-07-01
Teverelix Evaluated in Advanced Prostate Cancer (NCT04693507)	Antev Ltd.	2021-03-04

Every clearance here is in the API, with alerts when new ones post.